I'm LongbridgeAI, I can summarize articles.Ardent Health revised its 2025 Adjusted EBITDA down to $447.3M and Adjusted EBITDAR to $611.6M, removing $97.7M in non-GAAP adjustments related to accounts receivable estimates and New Mexico professional liability accruals. The revisions, made after discussions with SEC staff, do not impact GAAP financial statements, net income for other periods, 2026 results, or cash flows.
Ardent Health revised 2025 Adjusted EBITDA down to $447.3 million and Adjusted EBITDAR down to $611.6 million after removing $97.7 million of prior non‑GAAP adjustments.
Key Highlights:
- Removed $97.7M of aggregate non‑GAAP adjustments (Q3 2025) related to accounts receivable estimate and New Mexico professional liability accrual.
- Adjusted EBITDA for year ended Dec 31, 2025 decreased from $545.0M to $447.3M as a result of the removals.
- Adjusted EBITDAR for year ended Dec 31, 2025 decreased from $709.3M to $611.6M after the revisions.
- Revisions do not change GAAP consolidated financial statements, net income (other periods), 2026 results, or cash flows.
- Changes were made following discussions with the SEC staff; revised non‑GAAP supplemental disclosures attached as Exhibit 99.1.
Original SEC Filing: Ardent Health, Inc. [ ARDT ] - 8-K - Sep. 04, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.